425 related articles for article (PubMed ID: 36690929)
1. Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in Western China: a retrospective study.
Yang H; Tao Q; Li D; Yang J; Cai Q; Gan J; Huang S; Luo R
BMC Neurol; 2023 Jan; 23(1):35. PubMed ID: 36690929
[TBL] [Abstract][Full Text] [Related]
2. Drug treatment for spinal muscular atrophy type I.
Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD006281. PubMed ID: 31825542
[TBL] [Abstract][Full Text] [Related]
3. Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience.
Łusakowska A; Wójcik A; Frączek A; Aragon-Gawińska K; Potulska-Chromik A; Baranowski P; Nowak R; Rosiak G; Milczarek K; Konecki D; Gierlak-Wójcicka Z; Burlewicz M; Kostera-Pruszczyk A
Orphanet J Rare Dis; 2023 Aug; 18(1):230. PubMed ID: 37542300
[TBL] [Abstract][Full Text] [Related]
4. Nusinersen treatment of Spinal Muscular Atrophy Type 1 - results of expanded access programme in Poland.
Modrzejewska S; Kotulska K; Kopyta I; Grędowska E; Emich-Widera E; Tomaszek K; Paprocka J; Chmielewski D; Pilch J; Pietruszewski J; Lemska A; Zawadzka M; Mazurkiewicz-Bełdzińska M
Neurol Neurochir Pol; 2021; 55(3):289-294. PubMed ID: 33565602
[TBL] [Abstract][Full Text] [Related]
5. Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study.
Audic F; de la Banda MGG; Bernoux D; Ramirez-Garcia P; Durigneux J; Barnerias C; Isapof A; Cuisset JM; Cances C; Richelme C; Vuillerot C; Laugel V; Ropars J; Altuzarra C; Espil-Taris C; Walther-Louvier U; Sabouraud P; Chouchane M; Vanhulle C; Trommsdorff V; Pervillé A; Testard H; Lagrue E; Sarret C; Avice AL; Beze-Beyrie P; Pauly V; Quijano-Roy S; Chabrol B; Desguerre I
Orphanet J Rare Dis; 2020 Jun; 15(1):148. PubMed ID: 32532349
[TBL] [Abstract][Full Text] [Related]
6. Type I spinal muscular atrophy patients treated with nusinersen: 4-year follow-up of motor, respiratory and bulbar function.
Pane M; Coratti G; Sansone VA; Messina S; Catteruccia M; Bruno C; Sframeli M; Albamonte E; Pedemonte M; Brolatti N; Mizzoni I; D'Amico A; Bravetti C; Berti B; Palermo C; Leone D; Salmin F; De Sanctis R; Pera MC; Piastra M; Genovese O; Ricci F; Cavallina I; Masson R; Zanin R; Agosto C; Salomon E; Bruno I; Magnolato A; Bertini E; Tiziano FD; Bovis F; Mercuri E;
Eur J Neurol; 2023 Jun; 30(6):1755-1763. PubMed ID: 36880698
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland.
Tscherter A; Rüsch CT; Baumann D; Enzmann C; Hasselmann O; Jacquier D; Jung HH; Kruijshaar ME; Kuehni CE; Neuwirth C; Stettner GM; Klein A;
Neuromuscul Disord; 2022 May; 32(5):399-409. PubMed ID: 35337708
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Comparative Efficacy and Safety of Risdiplam and Nusinersen in Children with Type 1 Spinal Muscular Atrophy.
Kokaliaris C; Evans R; Hawkins N; Mahajan A; Scott DA; Sutherland CS; Nam J; Sajeev G
Adv Ther; 2024 Jun; 41(6):2414-2434. PubMed ID: 38705943
[TBL] [Abstract][Full Text] [Related]
9. Nusinersen for adults with spinal muscular atrophy.
Arslan D; Inan B; Kilinc M; Bekircan-Kurt CE; Erdem-Ozdamar S; Tan E
Neurol Sci; 2023 Jul; 44(7):2393-2400. PubMed ID: 36854931
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy of nusinersen and its evaluation in adolescent and adult patients with spinal muscular atrophy types 1 and 2.
Iwayama H; Kawahara K; Takagi M; Numoto S; Azuma Y; Kurahashi H; Yasue Y; Kawajiri H; Yanase A; Ito T; Kimura S; Kumagai T; Okumura A
Brain Dev; 2023 Feb; 45(2):110-116. PubMed ID: 36335004
[TBL] [Abstract][Full Text] [Related]
11. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
[TBL] [Abstract][Full Text] [Related]
12. Nusinersen for Spinal Muscular Atrophy Type I with Chronic Respiratory Failure: A Retrospective Study in South Korea.
Shin HJ; Na JH; Lee H; Lee YM
Yonsei Med J; 2023 Dec; 64(12):705-711. PubMed ID: 37992742
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany.
Pechmann A; Langer T; Schorling D; Stein S; Vogt S; Schara U; Kölbel H; Schwartz O; Hahn A; Giese K; Johannsen J; Denecke J; Weiß C; Theophil M; Kirschner J
J Neuromuscul Dis; 2018; 5(2):135-143. PubMed ID: 29689734
[TBL] [Abstract][Full Text] [Related]
14. Nusinersen induces detectable changes in compound motor action potential response in spinal muscular atrophy type 1 patients with severe impairment of motor function.
Ueda Y; Egawa K; Kawamura K; Ochi N; Goto T; Kimura S; Narugami M; Nakakubo S; Nakajima M; Manabe A; Shiraishi H
Brain Dev; 2024 Mar; 46(3):149-153. PubMed ID: 38103972
[TBL] [Abstract][Full Text] [Related]
15. Improvement in functional motor scores in patients with non-ambulatory spinal muscle atrophy during Nusinersen treatment in South Korea: a single center study.
Yoon JA; Jeong Y; Lee J; Lee DJ; Lee KN; Shin YB
BMC Neurol; 2024 Jun; 24(1):210. PubMed ID: 38902631
[TBL] [Abstract][Full Text] [Related]
16. The effects of nusinersen treatment on respiratory status of children with spinal muscular atrophy.
Hepkaya E; Kılınç Sakallı AA; Ülkersoy İ; Başkan AK; Arslan H; Meral Ö; Dilek TD; Güler S; Saltık S; Çokuğraş H
Pediatr Int; 2022 Jan; 64(1):e15310. PubMed ID: 36310036
[TBL] [Abstract][Full Text] [Related]
17. Nusinersen treatment of older children and adults with spinal muscular atrophy.
Konersman CG; Ewing E; Yaszay B; Naheedy J; Murphy S; Skalsky A
Neuromuscul Disord; 2021 Mar; 31(3):183-193. PubMed ID: 33608138
[TBL] [Abstract][Full Text] [Related]
18. [Clinical follow-up analysis of nusinersen in the disease-modifying treatment of pediatric spinal muscular atrophy].
Mao SS; Feng YJ; Xu L; Yao M; Xia Y; Jin JN; Wang LS; Chen TT; Chen XY; Zhang Y; Zhang H; Jiang Y; Li HB; Long Q; Gao F
Zhonghua Er Ke Za Zhi; 2022 Jul; 60(7):688-693. PubMed ID: 35768357
[No Abstract] [Full Text] [Related]
19. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Yamashita M; Rigo F; Hung G; Schneider E; Norris DA; Xia S; Bennett CF; Bishop KM
Lancet; 2016 Dec; 388(10063):3017-3026. PubMed ID: 27939059
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients.
Szabó L; Gergely A; Jakus R; Fogarasi A; Grosz Z; Molnár MJ; Andor I; Schulcz O; Goschler Á; Medveczky E; Czövek D; Herczegfalvi Á
Eur J Paediatr Neurol; 2020 Jul; 27():37-42. PubMed ID: 32456992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
